26 min listen
Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
ratings:
Length:
50 minutes
Released:
Apr 22, 2022
Format:
Podcast episode
Description
In part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (Marks, et al. Lancet Haematol, 2022): https://pubmed.ncbi.nlm.nih.gov/35358441/. We also discuss the previously published GRAALL study that evaluated rituximab in ALL (Maury, et al. NEJM, 2016, https://pubmed.ncbi.nlm.nih.gov/27626518/), and what we can conclude from the literature to date. The data surprises us, and makes us question our own practices!
Released:
Apr 22, 2022
Format:
Podcast episode
Titles in the series (24)
Episode 1: Surrogate Endpoints in AML by WolverHeme Happy Hour